share_log

EF Hutton Reiterates Buy on Sonnet BioTherapeutics, Maintains $6.7 Price Target

Benzinga ·  Jun 26, 2023 09:13

EF Hutton analyst Michael King reiterates Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and maintains $6.7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment